Two Phase I Studies, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative.

Trial Profile

Two Phase I Studies, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2013

At a glance

  • Drugs RG 4733 (Primary)
  • Indications Advanced breast cancer; Brain metastases; Cancer metastases; Lung cancer; Malignant melanoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 01 Jul 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Jan 2013 Planned end date changed from 1 Mar 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
    • 15 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top